Systemic Sclerosis
With numerous national and international meetings taking place throughout the year, choosing which conferences to attend can be difficult. While scientific programs remain a major draw, opportunities for networking, collaboration, career development and presenting research are often just as valuable. To help identify the meetings making the biggest impact across rheumatology, we asked members of the touchIMMUNOLOGY community to share the conferences they're prioritizing this year and what makes them worth attending.
The European Alliance of Associations for Rheumatology (EULAR) Congress 2026, held in London, UK, from 3–6 June 2026, brought together rheumatology experts from around the world to share the latest advances in research and clinical care.
Could personalized non-pharmacological care improve outcomes for people living with systemic lupus erythematosus and systemic sclerosis? In this interview from EULAR 2026, Dr Ioannis Parodis discusses the evidence underpinning EULAR recommendations and explores how patient education, psychosocial support and tailored lifestyle interventions can complement pharmacological treatment.
touchIMMUNOLOGY coverage of EULAR 2025: The 2025 European Alliance of Associations for Rheumatology (EULAR) Congress brought together leading rheumatologists, immunologists, and allied healthcare professionals from across Europe and beyond. Running from June 11–14 in Barcelona, the conference showcased the latest advances in immune-mediated ...
As part of our EULAR 2025 coverage, Dr Dinesh Khanna discusses early findings from the Breakfree-1 trial investigating BMS-986353, a next-generation CD19 CAR T-cell therapy, in severe, treatment-refractory autoimmune diseases. In this exclusive interview, Dr Khanna explores the rationale, mechanism, and encouraging early results in systemic sclerosis, highlighting robust CAR T expansion, immune reset, and meaningful clinical improvements in skin and lung outcomes.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Advances continue to be made in the treatment of systemic sclerosis (SSc, also termed ‘scleroderma’); however, it remains a challenging disease for both patients and for the clinicians caring for them. The purpose of this review is to highlight these ...
The SENSCIS Trial (NCT02597933) was a phase 3 randomised, double-blind, placebo controlled study, which investigated the efficacy and safety of nintedanib in the treatment of patients with systemic sclerosis associated interstitial lung disease. In this touchIMMUNOLOGY interview, it was a pleasure ...
It was an absolute pleasure to speak with Professor Kathryn Torok (UPMC & University of Pittsburgh Scleroderma Center, University of Pittsburgh, Pittsburgh, PA, USA) around the initial safety and clinical responses of patients with juvenile-onset systemic sclerosis treated with CD34...
In this interview, we talk with Professor Kathryn Torok (UPMC & University of Pittsburgh Scleroderma Center, University of Pittsburgh, Pittsburgh, PA, USA) around CD34-selected peripheral blood ASCT in patients with juvenile-onset systemic sclerosis (NCT03630211). This information is brought to ...
touchIMMUNOLOGY caught up with Dinesh Khanna (University of Michigan, Ann Arbor, MI, USA) to discuss the results of the NOVESA Phase 2a study of ziritaxestat in cutaneous systemic sclerosis (NCT03798366). His abstract entitled ‘A Phase 2a Randomized, Double-blind, Placebo-controlled Study ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
